A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination with Everolimus in Patients with CD70-Positive Metastatic Renal Cell Carcinoma

Trial Profile

A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination with Everolimus in Patients with CD70-Positive Metastatic Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2014

At a glance

  • Drugs Vorsetuzumab mafodotin (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 27 Jan 2014 Status changed from active, no longer recruiting to discontinued according to ClinicalTrials.gov record.
    • 15 Nov 2013 Planned end date changed from 30 Apr 2015 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 15 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top